Abstract 5790
Background
Genomic alterations have a profound impact on all aspects of cancer biology and therapy. Concomitant mutations involving multiple genes are intrinsically complex, and their relationship with biomarkers such as TMB and clinical outcomes such as drug response is only beginning to be explored. In this study, we systematically analyzed the impact of pairwise co-mutations of common genes on patient overall survival (OS).
Methods
We downloaded the publicly available TCGA datasets and used the LUAD lung adenocarcinoma subset for our pilot study. To limit noise, we restricted our attention to the top 48 most commonly mutated genes among LUAD patients. For each pair of genes g1 and g2 in this list, we compared the survival data of three groups of patients: those with g1 mutations only, those with g2 mutations only, and those with both g1 and g2 mutations. Kaplan-Meyer survival curves were plotted and p-values computed.
Results
We obtained a large number of double mutants (223 out of 1128 possible pairs, ∼20%) with significantly different OS from single mutants. There was a wide spectrum of “co-mutation potential”: on one hand, genes such as AHNAK2 and ANK2 readily co-mutated with many other genes, all leading to double mutants with distinguishing OS; on the other hand, genes such as DMD or DNAH9 co-mutated with few or no other genes that led to distinguishing double mutants. In terms of OS, double mutants could be put into three broad categories: those better than either single mutant (“synthetic rescue”), those worse (“synthetic lethal”), and those in between (“averaging”). Surprisingly, many double mutants exhibited synthetic-rescue behaviors. For example, ANK2- and LRP1B-mutant patients had very similar OS, but double-mutants exhibited significantly better OS than either single mutant (p < 0.001 in each case).
Conclusions
In our proof-of-concept study we systematically explored the impact of co-mutations on OS. A large number of double mutants exhibited “synthetic rescue” behaviors, and we pinpointed many distinguishing gene pairs for further investigation. It remains to be seen whether co-mutations of the same pair of genes always have the same effect across cancer types, and how they interact with other bio- and clinical markers.
Clinical trial identification
Legal entity responsible for the study
OrigiMed.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
Y-A. Dong: Employee: OrigiMed. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract